Pacira Biosciences Inc (PCRX) 13F Investor Activity Report (Q2 2026)

PCRX ranks #2446 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

PCRX is a top-conviction position for Doma Perpetual Capital Management LLC — at 16.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in PCRX belongs to BlackRock, Inc., but the position matters far more to Doma Perpetual Capital Management LLC, who has 16.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Wealth Enhancement Advisory Services, LLC has added to its PCRX position for two straight quarters, increasing it by $192.3K to reach $450.8K today.

State of Alaska, Department of Revenue has trimmed its PCRX position for two straight quarters, cutting it by $282.0K while still holding $496.0K.

PCRX is up 0% today, and institutions have been net buyers of $70.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

PCRX posted net income of $14.6M over the trailing twelve months, and currently trades at a P/E of 111.8.

• Profitable — net income of $14.6M over the trailing twelve months
• Revenue grew 5.7% year over year
• Net income improved year over year, from -$127.5M to $14.6M
• Generated $152.0M in positive operating cash flow
• Current ratio of 4.54x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.82x equity — within a conventional range